Best Practices in Alemtuzumab Administration: Practical Recommendations for Infusion in Patients With Multiple Sclerosis.

With the growing complexity of multiple sclerosis (MS) care, nursing professionals have increasing responsibility in managing clinical disease and treatment. Nursing professionals and other health care providers play important roles in educating patients about disease-modifying therapy options, the course of therapy, and managing potential adverse effects. A panel of nursing and MS experts was convened and used a modified Delphi method to reach consensus on best-practice recommendations for alemtuzumab infusion in MS patients.

Relapsing-remitting multiple sclerosis patients' experience with natalizumab: a phenomenological investigation.

This phenomenological investigation was undertaken to gain a better understanding of multiple sclerosis (MS) patients' experience with natalizumab (Tysabri; Biogen Idec Inc, Cambridge, MA) treatment and its impact on their quality of life (QOL). Twenty MS patients who were receiving natalizumab treatment were recruited by the physicians, nurse practitioners, nurses, and social worker of the William C. Baird Multiple Sclerosis Center in Buffalo, New York, between March 2009 and November 2009.

Emerging oral therapies for multiple sclerosis.

Despite notable advances in the understanding of multiple sclerosis (MS) and the availability of several treatment options, there is a need for therapies that are more effective, safe, convenient, and well tolerated. Several new oral MS therapies are being investigated. Because data on these new therapies continue to emerge, nurses will play a pivotal role in educating patients regarding the benefits and risks of potential treatments and in monitoring patients for response, safety, tolerability, and adherence.

Relapsing MS patients' experiences with glatiramer acetate treatment: a phenomenological study.

This study examined the experiences of a group of patients with relapsing multiple sclerosis who received glatiramer acetate for the treatment of their illness. Heideggerian phenomenologic research methods drove the data analysis process with the Atlas Qualitative Data Analysis software program. The sample was a diverse group of 20 men and women 39-64 years of age who had been diagnosed with MS 1-21 years and taking glatiramer acetate 1-7 years.